Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
TOKYO (Reuters) - Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as the company continues a restructuring push.
Takeda’s Q3 2025 earnings call highlighted strong revenue and margin growth, supported by robust product performance and operational efficiencies. The company raised full-year guidance and ...
TOKYO, Jan 30 (Reuters) - Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as ...
Takeda continues to advance multiple late-stage programs and is on track for three Phase 3 data readouts within the calendar year 2025. The company expects three regulatory filings in FY2025 ...
Takeda (NYSE:TAK) ADRs traded higher in the premarket on Thursday after the Japanese drugmaker raised its full-year outlook with its Q3 FY24 results and named Julie Kim, head of its U.S. business ...
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments ...
OSAKA, Japan, January 30, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024 ...
Additional Information About Takeda’s FY2024 Q3 YTD Results For more details about Takeda’s FY2024 Q3 YTD results, commercial progress, pipeline updates and other financial information ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results